Abstract:
Background: In patients with coronary heart disease, being overweight or obese is associated with better outcomes, a phenomenon known as the 'obesity paradox'. Despite the high prevalence of obesity in the United Sates, its effects on infarct size are largely unexplored.
Methods:
Prospective cross-sectional study of 102 consecutive patients admitted with acute myocardial infarction (MI). Standardized forms were used to collect data on body mass index (BMI), waist circumference (WC), cardiovascular risk factors, and medications. Peak troponin I and creatinine phosphokinase (CPK) were used to estimate infarct size. Epicardial and pericardial fat were measured by echocardiography. We used univariate and multivariate analyses to assess whether obesity was associated with infarct size. Correlations between BMI, WC and cardiac fat with cardiac biomarkers were also performed.
Results:
Mean age was 62±12 years, and 55% were men. Obesity was diagnosed in 69%.
On multivariate analysis, obesity was associated with greater infarct size in non-ST elevation MI (p=0.02). A positive correlation was observed between BMI and peak troponin I (rho=0.24, p=0.03), and both, BMI and WC had a positive correlations with CPK levels (rho=0.28, & rho=0.28, both p=0.02). However, in ST elevation MI, obesity was associated with smaller infarct size (p=0.05). Epicardial fat + pericardial fat had a negative correlation with peak CPK levels (rho=-0.36, p=0.05).
Conclusions:
We observed an opposite association between obesity and infarct size depending on the type of MI. These results were unexpected and may provide insight into the pathophysiology of the obesity paradox. (Word count: 244)
Introduction:
Obesity has become the epidemic of our time. Studies using body fat to diagnose obesity estimate that 1 of every 2 people are obese [1, 2] . Obesity contributes to the development of several cardiovascular (CV) risk factors, including hypertension, diabetes, metabolic syndrome, dyslipidemia, and obstructive sleep apnea, and may be an independent risk factor for coronary heart disease (CHD) [3] . However, large epidemiologic studies have shown that, compared to normal weight people, overweight and obese subjects with CV diseases, including CHD and following an acute myocardial infarction (MI), have better outcomes [4] , a phenomenon known as the "obesity paradox" [4] [5] [6] [7] [8] .
It is well accepted that cardiac biomarkers reflect myocardial damage. Of the several cardiac biomarkers, troponin I best reflects infarct size [9, 10] , showing an excellent correlation with infarct size, as measured by cardiac magnetic resonance (r=0.84), and has independent prognostic value [9] [10] [11] .
Despite obesity being prevalent in patients with MI, its effects on infarct size are largely unexplored. The aim of this study was to examine associations between obesity and cardiac fat with infarct size estimated by peak troponin I and creatinine phosphokinase (CPK) levels.
Methods: Study design and subject selection
A prospective cross-sectional study of 102 consecutive patients aged 30 to 89 years who were admitted to the coronary care unit from March 2010 to March 2011 with the diagnosis of MI was performed. We excluded patients with recent cocaine use, severe congestive heart failure (ejection fraction <20%), on hemodialysis, or with severe psychiatric conditions (unable to sign consent). Cardiology [12] .
Anthropometric measurements and obesity definition
Standardized forms were used to collect data on anthropometric variables. Body weight was measured with an electronic load cell scale to the nearest 0.01 kg. Height was measured to the nearest 0.1 cm using a fixed stadiometer. Waist circumference (WC) was determined using a measuring tape positioned at the high point of the iliac crest at the end expiration with the tape snug but not compressing the skin. Body mass index (BMI) was calculated as weight (kg) divided by height (m 2 ). Obesity was defined according to
American Heart Association as a BMI >30 kg/m 2 and/or WC >88 cm in women and >102 cm in men [3] .
Abstraction of clinical data
Standardized forms and medical records were used to obtain demographics and to determine the presence/absence of CV risk factors. Hypertension, diabetes, dyslipidemia, history of CHD and congestive heart failure were documented if self-reported by the patient or previously recorded on medical records, or if the patients were on medical therapy for those conditions. We further collected data on family history of premature CHD disease, smoking (current/former) and time of onset of chest pain. Screening for sleep apnea was performed by using the modified Berlin questionnaire [13] . Acute MI, non-ST elevation MI (NSTEMI), and ST elevation MI (STEMI) were defined according to American Heart Association and American College of Cardiology recommendations [14] .
Laboratory data collected included complete blood count, fasting basic metabolic profile, fasting lipid profile and cardiac biomarkers (troponin I and CPK). We recorded peak troponin I and CPK levels as surrogates of infarct size as previously described [9] [10] [11] . At the time of admission, medications were recorded, including the use of antihypertensives, diuretics, nitrates, antiarrhythmics, diabetes medications, statins or any other lipid lowering therapy, antiplatelet and anticoagulation therapy.
Echocardiographic and angiographic data
Transthoracic Doppler echocardiography was performed and reported according to the American Society of Echocardiography guidelines [15] . Cardiac fat, including epicardial adipose tissue (EAT), pericardial adipose tissue (PAT) and EAT plus PAT (EAT+PAT)
were measured by transthoracic echocardiography by a single operator (ARC) averaging 3 consecutive beats at end-systole in the parasternal long axis view [16] .
Intraobserver variability was performed by re-measuring 10 randomly selected patients one month later (r=0.97, p<0.0001). All measurements were performed blinded to clinical data of the patients. Angiographic data, including number of diseased vessels, as well as culprit vessel, were obtained from cardiac catheterization reports.
Statistical analyses
Data are reported as mean ± SD for continuous variables, and number and (%) for categorical variables. This study was designed to detect a difference of 4 ng/mL in peak troponin I between obese and non-obese subjects with 80% power and a two-tail α=0.05.
To assess baseline differences by type of MI and obesity status we used Students t-test for continuous variables and Chi 2 or Fishers exact test for categorical variables. We tested for normal distribution across the recorded variables, and we used the logarithm of peak troponin I and creatinine phosphokinase (CPK) due to the skewness of these continuous variables. Non-parametric correlations (Spearman) were performed to establish the association between BMI, WC, and cardiac fat with cardiac biomarkers. Due to significant difference in the peak troponin and CPK levels between NSTEMI and STEMI, analyses were reported separately. Two-tail p-values <0.05 were considered significant in advance. We performed univariate analyses to identify predictors of infarct size estimated by peak troponin I and CPK levels (p-value for inclusion <0.10).
Multivariate analyses were performed to identify independent predictors of infarct size after adjustment for age, sex, race, traditional cardiovascular risk factors, obstructive sleep apnea, ejection fraction, three vessel disease, and time of onset of chest pain (pvalue <0.05). Analyses were performed using JMP version 10.0 (SAS Institute, Cary, NC).
Results:
We enrolled 102 subjects ( 
Association between obesity and infarct size in NSTEMI patients
Baseline characteristics, as well as CV risk factors and cardiac biomarkers between obese and non-obese subjects with NSTEMI are shown in Table 2A . Compared to non-obese subjects, those with obesity were more likely to be women (70 vs. 42%, p=0.02) and diabetic (57 vs. 22%, p=0.004), had a high probability of having obstructive sleep apnea (68 vs. 13%, p<0.0001), and had higher peak troponin I (23.6±31 vs. 17.8±37ng/mL, p=0.04) and CPK levels (590±549 vs. 334±274U/L, p=0.05) - Figure 1A .
Significant univariate predictors for infarct size estimated by peak troponin I were hypertension (p=0.01), obesity (p=0.03) and possibly race (p=0.09), all of which were associated with higher troponin I. On multivariate analysis, obesity (p=0.02) remained a significant predictor of higher peak troponin I. Hypertension (p=0.01) and obesity (p=0.04) were significantly associated with higher peak CPK levels (Table 3A) . On multivariate analysis both obesity (p=0.02) and hypertension (p=0.02) remained significant predictors for higher peak CPK (table 4A) .
Correlations between BMI, WC, and cardiac fat with cardiac biomarkers are shown in Table 5A . BMI had a significant positive correlations with peak troponin I (rho=0.24, p=0.03) and CPK (rho=0.28, p=0.02), while WC had a significant positive correlation with peak CPK (rho=0.24, p=0.05).
Association between obesity and infarct size in STEMI patients
Baseline characteristics, as well as CV risk factors and cardiac biomarkers between obese and non-obese subjects with STEMI are shown in Table 2B . Compared to non-obese subjects, those with obesity had more EAT (7.1±2. Significant univariate predictors for infarct size estimated by peak troponin I were age (p=0.05) which was associated with higher peak troponin I, while obesity (p=0.06), EAT (p=0.05), and EAT+PAT (p=0.07) were associated with lower peak troponin I. On multivariate analysis, only obesity (p=0.02) remained as a significant predictor for lower peak troponin I. For peak CPK levels, age (p=0.06), history of CHD (p=0.04) and diabetes (p=0.06), were significant predictors of higher peak CPK (Table 3B) , while EAT+PAT (p=0.05) was associated with lower peak CPK. On multivariate analysis none of those remained significant, though there was a trend for diabetics (p=0.08) to have higher peak CPK (Table 4B) .
Correlations between BMI, WC, and cardiac fat with cardiac biomarkers are shown in table 5B. A trend towards a negative correlation was observed between EAT and EAT+PAT with peak troponin I (rho=-0.33, p=0.08, and rho=-0.34, p=0.07, respectively), while a significant negative correlation was observed between EAT+PAT with peak CPK (rho=-0.36, p=0.05). A trend towards a negative correlation was also observed between EAT and PAT with peak CPK levels (rho=-0.31, p=0.10, and rho=-0.34, p=0.06, respectively).
Discussion:
The main finding of our study is that obesity has a significant and independent association with infarct size at the time of acute MI. Interestingly, obesity was associated with greater infarct size in patients with NSTEMI, while in patients with STEMI it was associated with smaller infarct size. To our knowledge, this is the first study to report an association between cardiac fat and infarct size. We also observed that EAT+PAT is associated with smaller infarct size among STEMI patients.
There are only a few small studies that have examined the association of obesity on infarct size. Pingitore, et al, performed cardiac magnetic resonances in 89 patients after their first MI (at least 3 months old) to assess the extent of MI size. They observed a smaller infarct size in obese patients. In should be noted that >80% of their population were STEMI, and these findings are similar to our STEMI group [17] . In another study, Iglesias Bolanos, et al, studied the association between total and central obesity on infarct size in 40 men at the time of MI. Both BMI (r=0.43) and WC (r=0.47) showed a significant positive correlation with CPK (measured as AUC) [18] . These correlations are similar to our group of NSTEMI patients. It is important to note that Igleasias Bolanos study did not distinguished between STEMI and NSTEMI that in our study was noted to be an effect-modifier, meaning that obesity had opposite associations with infarct size by type of MI, and in fact, the interaction between BMI (but not WC) with peak troponin I by type of MI was statistically significant (p=0.005).
Furthermore, we believe this is the first study looking at the association of cardiac fat measured by echocardiography with infarct size. We observed that EAT+PAT was associated with smaller infarct size in STEMI patients. Much recent work has focused on the pathophysiology of cardiac fat in cardiovascular disease, and our findings though interesting, need to be replicated in larger studies.
Strengths and limitations
Strengths of our study include the careful adjustment for potential confounders, including obstructive sleep apnea, which is rarely accounted for in obesity studies. In addition, we excluded other potential confounders, including patients on hemodialysis and severe congestive heart failure. Limitations of our study include a relatively small sample size, shown that a single measurement of peak troponin I has an excellent correlation with infarct size [9] [10] [11] .
Conclusions
We observed significant associations between obesity and infarct size. Interestingly, the direction of these associations varied by type of MI. While obesity was associated with greater infarct size in NSTEMI patients, obesity was associated with smaller infarct size in STEMI. These results were unexpected and may provide insight into the pathophysiology of the obesity paradox. Figure shows in the Y axis (log) peak troponin I and (log) peak CPK and in the X axis obese vs. non-obese patients with STEMI. There is a significant difference in cardiac biomarkers with lower levels in the obese group. (21) 12 (12) 6 (6) 18 (62) 7 (24) 2 (7) 2 (7) 44 (60) 15 (21) 10 (14) 4 (5) 
